https://pages.htgaa.org/2026b/jose-sanchez/week-01-hw-project-ideas/index.htmlHTBAA Homework #1 (1) What I would like to biomanufacture and why My long-term vision is an allosteric “Bioswitch” version of an immune checkpoint inhibitor: pembrolizumab (Keytruda) that can be turned off on demand using light, to address chronic immune-related adverse effects associated with checkpoint blockade therapy. As Wolf, Mathony, and Niopek (Heidelberg University) describe in their 2026 Clinical and Translational Medicine invited letter, “Bioswitches: Towards programmable, on-demand control of therapeutic proteins,” most protein therapeutics act continuously for as long as they remain in the body, and “adverse effects such as off-target activity and toxicity may arise in consequence of prolonged drug activity and are difficult to mitigate once a patient has received the therapeutic” [1]. A light-switchable checkpoint inhibitor could shut off the inhibitor if severe adverse effects are observed without waiting for the drug to clear naturally.Hugoen